Pharma maker develops biosimilars to Lucentis, Eyelea.
Formulary Watch
Latest News
All News
Advertisement
Sandoz now has 2 biosimilars to the popular cancer drug.
Health groups had urged Trump to make a different choice.
PBM’s Medicare plan includes deep discounts
Researchers find lower lung function after inhaler change.
This is the eighth indication approved for Xarelto.
Here are the most exciting drugs in the pipeline right now.
Drug is the only respiratory therapy that can be given at home every 8 weeks.
New HIV prevention drug not indicated for women.
Drugstore retailers pull ranitidine and Zantac products off the shelves due to cancer concerns.
Advertisement
Drug is first 8-week treatment approved for this type of HCV.
How the first oral GLP-1 oral treatment for type 2 diabetes is unique and how it will be priced compared to other GLP-1 medications.
FDA limits packaging for this OTC medication.
Fentanyl citrate and ephedrine sulfate are among the medications affected.
FDA is evaluating risks to patients.
Targeted therapy gives new hope to patients with an aggressive form of lung cancer.
Health groups urge Trump to appoint Acting FDA Commissioner Ned Sharpless.
The new drug is an add-on to levodopa/carbidopa for Parkinson’s patients experiencing “off” episodes.
Use of these meds to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in liver failure in rare cases.
Teva’s generic EpiPen Jr. helps alleviate allergy drug shortage.
DEA scrambles to add qualified marijuana growers.
FDA approved the third oncology drug in the US that targets a key genetic driver of cancer, rather than a specific tumor.
Blockbuster drug could be key to Humira’s successor.
While FDA’s drug approval time is generally improving, the agency needs to speed up generic drug application reviews, according to a new report.
While FDA recently said Novartis and AveXis did not reveal data on their $2.1 million gene thaerpy for pediatric spinal muscular atrophy until after it was approved, Novartis is defending its actions.
Drug to treat prostate cancer is expected to produce a major windfall for two pharma makers.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Biosimilars in 2025: A year of firsts
2
What IRA drug prices will mean for PBMs, health plans and patients
3
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
4
FDA approves first postmenopausal libido treatment, Addyi
5
